PubMed Health⌕ Search

PubMed · 16032326

Re: Journal Standards - Editor's reply.

Abstract

Dr Jackson's concerns about citing non-peer-reviewed studies in the New Zealand Veterinary Journal (NZVJ) are shared by the editors and Editorial Board and have provoked considerable discussion about our policy and practice in this regard. Independent peer review remains a central part of the quality control process applied to the publication of scientific literature and is embraced by the NZVJ. All papers published in the NZVJ are scrutinised by the editors and Editorial Board, and those considered suitable are sent to two or three expert referees. In 2002, these comprised 195 people, of whom 36% were resident overseas. In addition, each paper is allocated a Guardian, a member of the Editorial Board specifically responsible for ensuring the adequacy of the peer-review process and providing an additional perspective regarding the quality of the paper. Papers are only accepted for publication after authors have satisfactorily addressed the issues raised by referees, Guardians and the Editor and sometimes by the Editorial Board. Thus, in addition to peer review, key quality-control roles are exercised at multiple points in the publication process by the Editor and Editorial Board to ensure the effectiveness, impartiality and integrity of the peer-review and editorial processes. Citation of data published in non-peer-reviewed sources in the NZVJ is discouraged but not precluded, in recognition of publications such as Surveillance and annual conference proceedings of New Zealand Veterinary Association (NZVA) special interest branches and the New Zealand Society of Animal Production as first repositories of disease reports and trial data often of substantial value and relevance to the scientific community. Many do not progress into the peer reviewed literature for reasons other than lack of quality and would otherwise be very difficult to access. As Dr Jackson points out, a substantial body of data generated in the deer industry has not yet appeared in peer-reviewed scientific journals, yet circulates widely in that industry. Considerable discussion preceded the permission granted authors to cite non-peer-reviewed studies to the extent evident in the December 2002 issue which was dedicated to feature review articles on the health and welfare of farmed deer. The proceedings of the annual seminars of the Deer Branch of the NZVA contain one of the most comprehensive records of studies on the nutrition, health and welfare of farmed deer available in the world. It was considered that the benefits of including discussion of these studies and exposing them to critical review outweighed the risks elaborated by Dr Jackson. However, the concerns raised by Dr Jackson and others prompted the Editorial Board to review the NZVJ's policy in this regard, which is now as follows: - Authors are specifically encouraged to cite peer-reviewed references wherever possible and particularly discouraged from citing their own publications in non-peer-reviewed sources. - Referees are specifically requested to scrutinise the use of non peer-reviewed references and make recommendations regarding alternatives or omission. - The Editor requests that authors: justify the use of non-peer-reviewed references; avoid the use of non-peer-reviewed citations more than 2 years old and; clearly distinguish references to nonpeer-reviewed references in the text of their papers, using qualifying statements such as preliminary data or non-peer-reviewed reportsetc. By limiting but not precluding citation of non-peer-reviewed studies, exposing them to specific scrutiny during the peer-review and editorial processes and by distinguishing them from peer-reviewed sources in the body of articles we aim to minimise the dangers of appearing to legitimise non-peer-reviewed data without losing the information value contained in some of these reports. There are many benefits of publishing in quality peer-reviewed journals such as the NZVJ, not least of which is the almost inevitable improvement in the quality and rigour of manuscripts after peer-review and the greatly increased opportunity for recognition and citation of peer-reviewed studies by others. Peer-reviewed journals remain the most widely accepted and established medium for communication and preservation of high-quality science. Authors and industry sectors that choose not to publish in peer-reviewed journals arguably limit the recognition and true progress of their science.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P D Jolly. 2003. Re: Journal Standards - Editor's reply.. https://doi.org/10.1080/00480169.2003.36367

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗